Protective Effect of Coenzyme Q10 Against Adriamycin-Induced Heart Damage

Protective Effect of Coenzyme Q10 Against Adriamycin-Induced Heart Damage

In this study, Okuma et al. examined whether coenzyme Q10 could reduce cardiotoxic effects associated with adriamycin (doxorubicin) chemotherapy. The research involved cancer patients who were being treated with adriamycin; one group received coenzyme Q10 in addition to their chemotherapy, while a comparison group received adriamycin without Q10. The dose of coenzyme Q10 was 90 mg/day, starting one week prior to the first adriamycin dose and continuing throughout the course of treatment.

Cardiac safety was assessed primarily using electrocardiograms (ECGs)—monitoring changes such as reductions in QRS voltage (a measure tied to heart muscle function) and prolongations of QT interval (a measure associated with risk of arrhythmias). In patients who did not receive coenzyme Q10, adriamycin induced significant reductions in QRS voltage and prolongation of ECG measures. In contrast, those who took coenzyme Q10 showed attenuated (less severe) changes in ECG measures: the QRS voltage drop was significantly less, and QT prolongation was prevented or much reduced.

This trial suggests that coenzyme Q10 at 90 mg/day has a protective effect on cardiac electrical activity in patients receiving adriamycin, helping to mitigate some of the cardiotoxic side effects as measured by ECG. While more modern trials with longer follow-up and more detailed endpoints are needed, this early evidence supports further exploration of Q10 as a cardioprotective adjunct in anthracycline chemotherapy.

Reference:

Okuma K, Furuta I, Ota K. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin]. Gan To Kagaku Ryoho. 1984;11(3):502-508